

MIOLIVE 2024 › MAIN PROGRAM › 05/06 FEBRUARY › ROME (IT)

mio 2024 5-6 FEBRUARY LIVER EDITION live

MEDITERRANEAN INTERVENTIONAL ONCOLOGY

HYBRID MEETING



**BROADEN
YOUR HORIZON.
SHARE YOUR
EXPERIENCE.
BE INNOVATIVE.**

PRACTICAL APPROACH TO LOCOREGIONAL TREATMENT IN ONCOLOGY



**UNIVERSITÀ
CATTOLICA
del Sacro Cuore**

Gemelli



Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore

MIOLIVE 2024 › MAIN PROGRAM › 05/06 FEBRUARY › ROME (IT) PRACTICAL APPROACH TO LOCOREGIONAL TREATMENT IN ONCOLOGY

COURSE DIRECTORS

Evis Sala › Luigi Natale › Roberto Iezzi

MIOLIVE SCIENTIFIC COMMITTEE

Okan Akhan › Josè Ignacio Bilbao › Antonio Gasbarrini
Felice Giuliani › Nahum Goldberg › Roberto Iezzi
Ahmad Sami › Vincenzo Valentini

HYBRID MEETING



BROADEN
YOUR HORIZON.
SHARE YOUR
EXPERIENCE.
BE INNOVATIVE.



UNIVERSITÀ
CATTOLICA
del Sacro Cuore

Gemelli



Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore

09:00 OPENING REMARKS AND WELCOME ADDRESS

09:05 **OPENING LECTURE** “The role of Radiologist in Value-Based Healthcare”

I SESSION 09:20/13:00

GRAN JURY » Okan Akhan - Dimitrios Filippiadis – Fernando Gomez - Nahum Goldberg

09:20 **EARLY STAGE HCC**

● **WHAT'S NEW IN 2024? THE 3 PUBLISHED ARTICLES**

OF THE LAST YEAR WITH GREATEST IMPACT ON PATIENT MANAGEMENT (10 MINUTES) » Laura Crocetti

EXPERT PANEL DISCUSSION: INTERACTIVE MULTIDISCIPLINARY TREATMENT DECISION

MODERATOR » Roberto Iezzi

PANELIST » Okan Akhan, Dimitrios Filippiadis, Vladimir Dimov, Antonio Gasbarrini, Felice Giuliante, Nahum Goldberg, Maurizio Pompili, Fernando Gomez, Laura Crocetti

DISCUSSANT » Tobias Jakobs

● **EARLY STAGE CASES FROM MIOLIVE 2023:**

WERE THE EXPERTS RIGHT? WHAT HAVE WE LEARNED?

● **EARLY STAGE CASES FROM MIOLIVE 2019:**

TRENDS AND CHANGES IN TREATMENT INDICATIONS OVER THE LAST 5YS?

● **NEW CASES**

● **EARLY HCC SURVEY RESULTS PRACTICAL QUESTIONS FOR DEFINING REAL-LIFE PRACTICE
SENATE VS. PEOPLE OF ROME (AUDIENCE DISCUSSION)**

THE CASE FOR AGGRESSIVE SURGERY » Guido Torzilli
CENTER EXPERIENCE/AVAILABILITY & IMPACT ON OUTCOME » Irene Bargellini
WHICH DEVICE FOR WHICH LESION? » Francesco Rosario Grasso
IMAGE-GUIDANCE SOFTWARES: WHICH EVIDENCE? » AnnaMaria Ierardi
MULTIPROBE APPROACH: ADVANTAGES / DISADVANTAGES » Reto Bale
COMBINED TREATMENT: ADVANTAGES / DISADVANTAGES » Tobias Jakobs
PERCUTANEOUS SEGMENTECTOMY: ADVANTAGES / DISADVANTAGES » Pierleone Lucatelli
RADIATION SEGMENTECTOMY: Advantages / Disadvantages » Thomas Helmberger

12:00 ■ **LIVE CASES**

12:30 **CURRENT PERCEPTIONS OF IO AMONG COMPETITIVE MEDICAL DISCIPLINES FOR THE TREATMENT OF CRC**

MODERATORS » Manca nome Gambacorta, Manca nome Tortora
ESSO POINT OF VIEW: WHICH IS THE ROLE FOR CURATIVE ABLATIVE LT? » Stefan Staettner
ESMO POINT OF VIEW: WHICH IS THE ROLE FOR PALLIATIVE INTRA-ARTERIAL LT? » Arnold Dirk
IS THERE A ROLE FOR COMBINING INTERVENTIONAL RADIOLOGY AND INTERVENTIONAL RADIOTHERAPY? » Luca Tagliaferri
ETF POINT OF VIEW: FUTURE ROLE OF BIG DATA AND RADIOMIC FOR SELECTING THE BEST TREATMENT » G. Cazzato
IMMUNOTHERAPY AND IO: WHICH ROLE

13:40 ■ **LIVE CASES**

■ **II SESSION** 14:00/18:30

GRAN JURY » Jafar Golzarian, David Madoff - Marc Sapoval,
José Ignacio Bilbao, Thierry de Baere, Thomas Helmberger

14:00 **★ MIOLIVE MEETS GEST SESSION**

15:00 **■ LECTURE ARTIFICIAL INTELLIGENCE AND INTERVENTIONAL RADIOLOGY:
READY FOR IT? »** Fernando Gomez

15:15 **■ PRE-RECORDED DEMONSTRATIVE CASE (LIVE DISCUSSION)**

15:30 **■ LIVE CASE**

15:00 **■ THE GUT MICROBIOME & HCC: WHICH IMPACT FOR TREATMENT? »** Fernando Gomez

10:00 **EXPERT PANEL DISCUSSION: INTERMEDIATE STAGE HCC**

WHAT'S NEW IN 2024? THE BEST 3 PUBLISHED ARTICLES

I HAVE READ IN THE LAST YEAR WITH IMPACT ON PATIENT MANAGEMENT

INTERACTIVE MULTIDISCIPLINARY TREATMENT DECISION

MODERATOR » Maurizio Pompili

PANELIST » Bora Peymicioglu, Katerina Malagari, Tobias Jakobs, Pierleone Lucatelli, Francesca Ponziani,
Marco Biolato, Francesco Ardito – Alban Denys, Alessandro Vitale, Thierry de Baere

DISCUSSANT » Thomas Helmberger

- INTERMEDIATE-STAGE CASES FROM MIOLIVE 2022: Were the experts right? What have we learned?
- INTERMEDIATE STAGE CASES FROM MIOLIVE 2019: How treatment indications changed?
- NEW CASES
- INTERMEDIATE HCC SURVEY RESULTS PRACTICAL QUESTIONS FOR DEFINING REAL-LIFE PRACTICE SENATE VS. PEOPLE OF ROME (AUDIENCE DISCUSSION)

A. INTERMEDIATE STAGE CLASSIFICATION » Alessandro Vitale

B. CTACE/DEB-TACE/DEGRADABLE-TACE/TAE: Which evidence? » Olivier Pellerin

C. TACE VS TARE: WHICH EVIDENCE? WHICH IS THE BEST PATIENT? » Jens Ricke

D. SELECTIVE / SUPERSELECTIVE / ULTRASELECTIVE: TIME FOR CURATIVE TACE? » Franco Orsi

18:15  **PRE-RECORDED DEMONSTRATIVE CASE (LIVE DISCUSSION)**

18:30  **LIVE CASE**

19:00 PLENARY DISCUSSION ON PATIENTS TREATED

III SESSION 09:00/13:00

GRAN JURY » Martijn Meijerink, Francesco De Cobelli, Jens Ricke, Adam Hatzidakis

09:00 **PRE-RECORDED DEMONSTRATIVE CASE (LIVE DISCUSSION)**09:15 **LIVE CASE**09:30 **HONORARY LECTURE**
CUTTING-EDGE IMAGING » Afshin Gangi09:45 **IO OF THE LIVER BEYOND HCC AND CRC**
MODERATORS » Afshin Gangi, Martijn Meijerink
▪ BREAST » Thomas Vogl
▪ NEUROENDOCRINE » Cristina Mosconi
▪ CHOLANGIOCARCINOMA » Peter Reimer
▪ ROLE OF PALLIATION FOR OTHER METS » XXXX10:45 **LIVE CASE**11:00 **PRE-RECORDED DEMONSTRATIVE CASE (LIVE DISCUSSION)**11:15 **EXPERT PANEL DISCUSSION: ADVANCED STAGE HCC**
▪ WHAT'S NEW IN 2024? THE BEST 3 PUBLISHED ARTICLES I HAVE READ
IN THE LAST YEAR WITH IMPACT ON PATIENT MANAGEMENT » Bruno Sangro

INTERACTIVE MULTIDISCIPLINARY TREATMENT DECISION

MODERATOR » Roberto Iezzi

ADVANCED STAGE CASES FROM MIOLIVE 2020: WERE THE EXPERTS RIGHT? WHAT HAVE WE LEARNED?PANELIST » Jens Ricke, Roberto Cianni, Carlo Spreafico, Massimo Venturini,
Francesco De Cobelli, Irene Bargellini, Bhoori Sherrie, Bruno Sangro

DISCUSSANT » Martijin Meijerink

- ADVANCED STAGE CASES FROM MIOLIVE 2023: WERE THE EXPERTS RIGHT? WHAT HAVE WE LEARNED?
- INTERMEDIATE STAGE CASES FROM MIOLIVE 2019: HOW TREATMENT INDICATIONS CHANGED?
- NEW CASES
- ADVANCED HCC SURVEY RESULTS PRACTICAL QUESTIONS FOR DEFINING REAL-LIFE PRACTICE
SENATE VS. PEOPLE OF ROME (AUDIENCE DISCUSSION)

A. ADVANCED STAGE CLASSIFICATION » Irene Bargellini

B. CHEMOEMBOLIZATION IN ADVANCED STAGE: WHICH TACE? WHICH EVIDENCE? » Federico Collettini

C. TARE & ADVANCED STAGE: WHICH EVIDENCE? » Francesco De Cobelli

D. IMMUNOTHERAPY & LT IN ADVANCED STAGE: WHICH EVIDENCE? » Bora Peyrnicioğlu

12:55

■ **PRE-RECORDED DEMONSTRATIVE CASE (LIVE DISCUSSION)**

13:05

■ **LIVE CASE**

13:15

INDUSTRY SYMPOSIUM (NON CME/ECM)

■ **IV SESSION** 14:00/18:30

GRAN JURY » Marcelo Guimaraes, Robert Lewandoski, Philippe Pereira, Aleksandar Gjoreski, Jean Palussiere, Attila Kovacs

14:00

✦ **MIOLIVE MEETS CIRSE**

NEXT RESEARCH & IASIOS

MODERATORS » Philippe Pereira, Luigi Natale

QUALITY ASSURANCE IN IO PRACTICE » Afshin Gangi

IASIOS: THE IMPORTANCE OF GETTING YOUR SERVICE LINE & PATIENT PATHWAY ACCREDITED » Laura Crocetti

IO AS FOURTH PILLAR OF ONCOLOGY: WHERE ARE WE AND WHERE ARE WE GOING? » Philippe Pereira

NEXT RESEARCH: IMPROVING THE IO RESEARCH INFRASTRUCTURE » Thomas Helmberger

15:00

HONORARY LECTURE

IO AT 25 YEARS: CLINICAL TRIALS WE STILL NEED TO SEE » Nahum Shraga Goldberg

15:15

■ **PRE-RECORDED DEMONSTRATIVE CASE: ALEKSANDAR GJORESKI COMBINED TREATMENT & MCRC**

15:30

■ **LIVE CASE**

15:45

✦ **MIOLIVE MEETS SIO**

CUTTING EDGE BASIC SCIENCE TO PROPEL CLINICAL IO

15:00

ABSTRACT SESSION

PLENARY DISCUSSION ON PATIENTS TREATED

18:45

END